Podcasts about marwan sabbagh

Could long Covid cause other long-term cognitive issues? Barrow Neurological Institute's Dr. Marwan Sabbagh joins us to explain the results of a new study. 

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/future-frontiers-the-future-landscape-of-alzheimers-therapeutics/26348/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer's disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer's disease.

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/comparative-efficacy-subq-vs-intravenous-dmts-in-alzheimers-disease/26347/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer's disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer's disease.

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/therapeutic-insights-navigating-the-use-and-challenges-of-disease-modifying-therapies/26346/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer's disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer's disease.

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/breaking-ground-the-latest-data-on-ad-disease-modifying-therapies/26345/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer's disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer's disease.

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/markers-of-memory-pathological-biomarkers-of-clinical-mci-due-to-ad/26344/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer's disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer's disease.

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/precision-imaging-mris-critical-role-in-early-mci-ad-diagnosis/26343/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer's disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer's disease.

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/beyond-guesswork-validated-methods-for-mci-assessment-in-alzheimers-diagnosis/26342/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer's disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer's disease.

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/inequity-and-illness-understanding-mci-disease-course-and-severity-for-racial-minorities/26341/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer's disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer's disease.

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-subtle-onset-understanding-early-mci-ad-symptoms/26340/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer's disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer's disease.

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/dementia-on-a-spectrum-preclinical-stages-of-mci-in-ad/26339/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer's disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer's disease.

View Show Notes From This Episode Get Free Weekly Health Tips from Dr. Hyman Sign Up for Dr. Hyman's Weekly Longevity Journal Lifestyle and dietary factors are widely accepted as key drivers of disease among cardiologists, oncologists, and endocrinologists, however the impact of diet and lifestyle on our brain health still remains largely on the margins. And, while there are certainly other factors, creating healthy daily habits can make a significant difference. In this episode, Dr. Hyman speaks with Dr. Marwan Sabbagh, Dr. Richard Isaacson, and Dr. Jay Lombard about the role of genetics in brain disorders, lifestyle habits you can start right now to reduce your risk or reverse symptoms, and why we need to look at bacteria as a cause of neurodegenerative disease. This episode is brought to you by Rupa Health and AG1. Streamline your lab orders with Rupa Health. Access more than 3,000 specialty lab tests and register for a FREE live demo at RupaHealth.com. Get your daily serving of vitamins, minerals, adaptogens, and more with AG1. Head to DrinkAG1.com/Hyman and get a year's worth of D3 and five Travel Packs for FREE with your first order. Learn more about your ad choices. Visit megaphone.fm/adchoices

The key to understanding Alzheimer's disease could be in our genes. While the cause of Alzheimer's is still unknown, mounting research shows that carrying multiple copies of certain genes — like genetic variant ApoE4 — can significantly increase the likelihood of developing Alzheimer's. By studying genetics and gene therapy, scientists are learning more about how genes play a role in Alzheimer's disease and what can be done for prevention. Barrow Neurological Institute's neurologist, author, and Alzheimer's expert Dr. Marwan Sabbagh joins Being Patient to discuss how scientists are seeking to prevent Alzheimer's through genetic research. Sabbagh, a board-certified behavioral neurologist at Barrow's Alzheimer's and Memory Disorders Program and a professor at the institute's department of neurology, has served as the lead investigator on several prominent national Alzheimer's prevention and treatment clinical trials. In this talk, he'll speak about how genetic research, like that on the ApoE4 gene, can help us learn more about Alzheimer's and how it can be prevented. This Live Talk is sponsored by Alzheon.

The key to understanding Alzheimer's disease could be in our genes. While the cause of Alzheimer's is still unknown, mounting research shows that carrying multiple copies of certain genes — like genetic variant ApoE4 — can significantly increase the likelihood of developing Alzheimer's. By studying genetics and gene therapy, scientists are learning more about how genes play a role in Alzheimer's disease and what can be done for prevention. Barrow Neurological Institute's neurologist, author, and Alzheimer's expert Dr. Marwan Sabbagh joins Being Patient to discuss how scientists are seeking to prevent Alzheimer's through genetic research. Sabbagh, a board-certified behavioral neurologist at Barrow's Alzheimer's and Memory Disorders Program and a professor at the institute's department of neurology, has served as the lead investigator on several prominent national Alzheimer's prevention and treatment clinical trials. In this talk, he'll speak about how genetic research, like that on the ApoE4 gene, can help us learn more about Alzheimer's and how it can be prevented. This Live Talk is sponsored by Alzheon. Watch now to learn more about the genetics of Alzheimer's disease. If you loved watching this Live Talk, visit our website to find more of our Alzheimer's coverage and subscribe to our newsletter: https://www.beingpatient.com/ Follow Being Patient: Twitter:   / being_patient_   Instagram:   / beingpatientvoices   Facebook:   / beingpatientalzheimers   LinkedIn:   / being-patient   Being Patient is an editorially independent journalism outlet for news and reporting about brain health, cognitive science, and neurodegenerative diseases. In our Live Talk series on Facebook, former Wall Street Journal Editor and founder of Being Patient, Deborah Kan, interviews brain health experts and people living with dementia.

atching and accurately identifying a neurodegenerative disease like Alzheimer's or another form of dementia early can make all the difference in the world to a patient and their loved ones: An early diagnosis means more time to plan for the future, join a clinical trial testing cutting-edge disease-modifying treatments, making lifestyle changes to slow symptoms, or spending more time with loved ones. On the other hand, a misdiagnosis could mean that patients receive the wrong medications, causing harm — and unfortunately misdiagnoses are all too common when it comes to dementia. Why is this the case, and what can patients do about it? Neurologist, author, and Alzheimer's expert Dr. Marwan Sabbagh joins Being Patient Live Talks to discuss why dementias are so difficult to diagnose. Sabbagh, a board-certified behavioral neurologist at Barrow Neurological Institute's Alzheimer's and Memory Disorders Program and a professor at the institute's Department of Neurology, has served as the lead investigator on a number of prominent national Alzheimer's prevention and treatment clinical trials. In this talk, he'll speak to the factors that make dementia so difficult to diagnose accurately for experts and clinicians — as well as what patients and their families can do to advocate for an accurate diagnosis and a faster response to brain health concerns. Watch the full video to learn more about what caregivers and people living with dementia should know about diagnosis. If you loved watching this Live Talk, visit our website to find more of our Alzheimer's coverage and subscribe to our newsletter: https://www.beingpatient.com/ Follow Being Patient: Twitter:   / being_patient_   Instagram:   / beingpatientvoices   Facebook:   / beingpatientalzheimers   LinkedIn:   / being-patient   Being Patient is an editorially independent journalism outlet for news and reporting about brain health, cognitive science, and neurodegenerative diseases. In our Live Talk series on Facebook, former Wall Street Journal Editor and founder of Being Patient, Deborah Kan, interviews brain health experts and people living with dementia. Check out our latest Live Talks: https://www.beingpatient.com/category...#Alzheimers #Dementia #BrainTalk #Diagnosis

När mer än fyra tusen internationella Alzheimerforskare samlades i Göteborg våren 2023 så var det många positiva tongångar. En ny typ av läkemedel håller på att godkännas och mycket forskning ligger i pipeline. En av föreläsarna professorn i neurologi Marwan Sabbagh från Phoenix i Arizona i USA menade till och med att det kan komma så bra behandlingar mot Alzheimer inom en snar framtid att sjukdomen kommer att gå att leva med som en kronisk sjukdom, på liknande sätt som behandlingar har utvecklats mot bland annat diabetes och hiv.Oklart vilken förbättring Alzheimläkemedel gerMen även om läkemedlen visar effekt så är professorn emeritus i farmakologi och psykiatri Ezio Giacobini kritisk och undrar hur mycket bättre livet blir för en patient i praktiken, även om de nya monoklonala antikropparna visar på en möjlighet att minska mängden proteiner som leder till Alzheimer. Störd sömn kan leda till AlzheimerHelsinborgsfödda Samira Parhizkar, som nu forskar i St Louise i USA, har visat i musstudier att hjärnans mikroglia som ska städa bort skadliga proteiner som kan leda till Alzheimer - att de fungerar sämre vid störd sömn. Något som hon menar går att överföra till människor. För att minska risken för störd sömn menar hon att det gäller att skapa god sömnkvalitet. Medverkar gör också Johan Sandin från Alzecure vid Karolinska institutet och Maria Ankarcrona, professor i experimentell neurogeriatrik på Karolinska institutet Programledare och producent: Annika ÖstmanAnnika.Ostman@sr.se

Go online to PeerView.com/GAZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses strategies for optimizing the biomarker-based diagnosis of Alzheimer's disease early in the disease course and the selection of appropriate patients who might benefit from novel disease-modifying therapies, as well as a comprehensive care model for the multidisciplinary management of patients with Alzheimer's disease. Upon completion of this activity, participants should be better able to: Apply current and emerging diagnostic tools to optimize the biomarker-based diagnosis of AD early in the disease course; Select appropriate patients with AD who may benefit from novel disease-modifying therapies based on an understanding of their mechanisms of action, efficacy, and safety profiles; and Utilize a comprehensive care model to optimize the multidisciplinary management of patients with AD

Go online to PeerView.com/DEC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer's disease (AD) is a devastating yet highly prevalent condition, affecting 10% of people aged 65 years and older and increasing in prevalence as the population ages. Recent advances in disease-modifying therapies have allowed for the possibility of reductions in disease progression and improved patient outcomes. Significant advances have also been made in identifying and testing biomarkers for AD that may aid in the early diagnosis of disease, facilitate patient selection for treatment, and monitor therapeutic response. In this activity, based on a recent live event, a panel of expert faculty provide training in the appropriate integration of validated and emerging cerebrospinal fluid (CSF) and plasma biomarkers into the AD diagnostic workup to identify early-stage AD in symptomatic patients. The faculty utilize a case-based approach to model the application and interpretation of fluid biomarkers in clinical practice, as well as highlight advantages and limitations associated with currently available and emerging CSF and plasma biomarkers. Upon completion of this activity, participants should be better able to: Apply validated fluid biomarkers to facilitate a timely neuropathological diagnosis of AD in symptomatic patients; Describe the limitations and advantages associated with currently available and emerging fluid diagnostics; and Integrate emerging plasma biomarkers into the diagnostic workup through appropriate application and accurate interpretation to improve early diagnosis and precision management of AD

Go online to PeerView.com/DEC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer's disease (AD) is a devastating yet highly prevalent condition, affecting 10% of people aged 65 years and older and increasing in prevalence as the population ages. Recent advances in disease-modifying therapies have allowed for the possibility of reductions in disease progression and improved patient outcomes. Significant advances have also been made in identifying and testing biomarkers for AD that may aid in the early diagnosis of disease, facilitate patient selection for treatment, and monitor therapeutic response. In this activity, based on a recent live event, a panel of expert faculty provide training in the appropriate integration of validated and emerging cerebrospinal fluid (CSF) and plasma biomarkers into the AD diagnostic workup to identify early-stage AD in symptomatic patients. The faculty utilize a case-based approach to model the application and interpretation of fluid biomarkers in clinical practice, as well as highlight advantages and limitations associated with currently available and emerging CSF and plasma biomarkers. Upon completion of this activity, participants should be better able to: Apply validated fluid biomarkers to facilitate a timely neuropathological diagnosis of AD in symptomatic patients; Describe the limitations and advantages associated with currently available and emerging fluid diagnostics; and Integrate emerging plasma biomarkers into the diagnostic workup through appropriate application and accurate interpretation to improve early diagnosis and precision management of AD

Go online to PeerView.com/GAZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses strategies for optimizing the biomarker-based diagnosis of Alzheimer's disease early in the disease course and the selection of appropriate patients who might benefit from novel disease-modifying therapies, as well as a comprehensive care model for the multidisciplinary management of patients with Alzheimer's disease. Upon completion of this activity, participants should be better able to: Apply current and emerging diagnostic tools to optimize the biomarker-based diagnosis of AD early in the disease course; Select appropriate patients with AD who may benefit from novel disease-modifying therapies based on an understanding of their mechanisms of action, efficacy, and safety profiles; and Utilize a comprehensive care model to optimize the multidisciplinary management of patients with AD

Go online to PeerView.com/DEC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer's disease (AD) is a devastating yet highly prevalent condition, affecting 10% of people aged 65 years and older and increasing in prevalence as the population ages. Recent advances in disease-modifying therapies have allowed for the possibility of reductions in disease progression and improved patient outcomes. Significant advances have also been made in identifying and testing biomarkers for AD that may aid in the early diagnosis of disease, facilitate patient selection for treatment, and monitor therapeutic response. In this activity, based on a recent live event, a panel of expert faculty provide training in the appropriate integration of validated and emerging cerebrospinal fluid (CSF) and plasma biomarkers into the AD diagnostic workup to identify early-stage AD in symptomatic patients. The faculty utilize a case-based approach to model the application and interpretation of fluid biomarkers in clinical practice, as well as highlight advantages and limitations associated with currently available and emerging CSF and plasma biomarkers. Upon completion of this activity, participants should be better able to: Apply validated fluid biomarkers to facilitate a timely neuropathological diagnosis of AD in symptomatic patients; Describe the limitations and advantages associated with currently available and emerging fluid diagnostics; and Integrate emerging plasma biomarkers into the diagnostic workup through appropriate application and accurate interpretation to improve early diagnosis and precision management of AD

Go online to PeerView.com/DEC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer's disease (AD) is a devastating yet highly prevalent condition, affecting 10% of people aged 65 years and older and increasing in prevalence as the population ages. Recent advances in disease-modifying therapies have allowed for the possibility of reductions in disease progression and improved patient outcomes. Significant advances have also been made in identifying and testing biomarkers for AD that may aid in the early diagnosis of disease, facilitate patient selection for treatment, and monitor therapeutic response. In this activity, based on a recent live event, a panel of expert faculty provide training in the appropriate integration of validated and emerging cerebrospinal fluid (CSF) and plasma biomarkers into the AD diagnostic workup to identify early-stage AD in symptomatic patients. The faculty utilize a case-based approach to model the application and interpretation of fluid biomarkers in clinical practice, as well as highlight advantages and limitations associated with currently available and emerging CSF and plasma biomarkers. Upon completion of this activity, participants should be better able to: Apply validated fluid biomarkers to facilitate a timely neuropathological diagnosis of AD in symptomatic patients; Describe the limitations and advantages associated with currently available and emerging fluid diagnostics; and Integrate emerging plasma biomarkers into the diagnostic workup through appropriate application and accurate interpretation to improve early diagnosis and precision management of AD

Go online to PeerView.com/GAZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses strategies for optimizing the biomarker-based diagnosis of Alzheimer's disease early in the disease course and the selection of appropriate patients who might benefit from novel disease-modifying therapies, as well as a comprehensive care model for the multidisciplinary management of patients with Alzheimer's disease. Upon completion of this activity, participants should be better able to: Apply current and emerging diagnostic tools to optimize the biomarker-based diagnosis of AD early in the disease course; Select appropriate patients with AD who may benefit from novel disease-modifying therapies based on an understanding of their mechanisms of action, efficacy, and safety profiles; and Utilize a comprehensive care model to optimize the multidisciplinary management of patients with AD

Go online to PeerView.com/GAZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses strategies for optimizing the biomarker-based diagnosis of Alzheimer's disease early in the disease course and the selection of appropriate patients who might benefit from novel disease-modifying therapies, as well as a comprehensive care model for the multidisciplinary management of patients with Alzheimer's disease. Upon completion of this activity, participants should be better able to: Apply current and emerging diagnostic tools to optimize the biomarker-based diagnosis of AD early in the disease course; Select appropriate patients with AD who may benefit from novel disease-modifying therapies based on an understanding of their mechanisms of action, efficacy, and safety profiles; and Utilize a comprehensive care model to optimize the multidisciplinary management of patients with AD

Go online to PeerView.com/DEC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer's disease (AD) is a devastating yet highly prevalent condition, affecting 10% of people aged 65 years and older and increasing in prevalence as the population ages. Recent advances in disease-modifying therapies have allowed for the possibility of reductions in disease progression and improved patient outcomes. Significant advances have also been made in identifying and testing biomarkers for AD that may aid in the early diagnosis of disease, facilitate patient selection for treatment, and monitor therapeutic response. In this activity, based on a recent live event, a panel of expert faculty provide training in the appropriate integration of validated and emerging cerebrospinal fluid (CSF) and plasma biomarkers into the AD diagnostic workup to identify early-stage AD in symptomatic patients. The faculty utilize a case-based approach to model the application and interpretation of fluid biomarkers in clinical practice, as well as highlight advantages and limitations associated with currently available and emerging CSF and plasma biomarkers. Upon completion of this activity, participants should be better able to: Apply validated fluid biomarkers to facilitate a timely neuropathological diagnosis of AD in symptomatic patients; Describe the limitations and advantages associated with currently available and emerging fluid diagnostics; and Integrate emerging plasma biomarkers into the diagnostic workup through appropriate application and accurate interpretation to improve early diagnosis and precision management of AD

Go online to PeerView.com/DEC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer's disease (AD) is a devastating yet highly prevalent condition, affecting 10% of people aged 65 years and older and increasing in prevalence as the population ages. Recent advances in disease-modifying therapies have allowed for the possibility of reductions in disease progression and improved patient outcomes. Significant advances have also been made in identifying and testing biomarkers for AD that may aid in the early diagnosis of disease, facilitate patient selection for treatment, and monitor therapeutic response. In this activity, based on a recent live event, a panel of expert faculty provide training in the appropriate integration of validated and emerging cerebrospinal fluid (CSF) and plasma biomarkers into the AD diagnostic workup to identify early-stage AD in symptomatic patients. The faculty utilize a case-based approach to model the application and interpretation of fluid biomarkers in clinical practice, as well as highlight advantages and limitations associated with currently available and emerging CSF and plasma biomarkers. Upon completion of this activity, participants should be better able to: Apply validated fluid biomarkers to facilitate a timely neuropathological diagnosis of AD in symptomatic patients; Describe the limitations and advantages associated with currently available and emerging fluid diagnostics; and Integrate emerging plasma biomarkers into the diagnostic workup through appropriate application and accurate interpretation to improve early diagnosis and precision management of AD

Go online to PeerView.com/GAZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses strategies for optimizing the biomarker-based diagnosis of Alzheimer's disease early in the disease course and the selection of appropriate patients who might benefit from novel disease-modifying therapies, as well as a comprehensive care model for the multidisciplinary management of patients with Alzheimer's disease. Upon completion of this activity, participants should be better able to: Apply current and emerging diagnostic tools to optimize the biomarker-based diagnosis of AD early in the disease course; Select appropriate patients with AD who may benefit from novel disease-modifying therapies based on an understanding of their mechanisms of action, efficacy, and safety profiles; and Utilize a comprehensive care model to optimize the multidisciplinary management of patients with AD

Go online to PeerView.com/DEC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer's disease (AD) is a devastating yet highly prevalent condition, affecting 10% of people aged 65 years and older and increasing in prevalence as the population ages. Recent advances in disease-modifying therapies have allowed for the possibility of reductions in disease progression and improved patient outcomes. Significant advances have also been made in identifying and testing biomarkers for AD that may aid in the early diagnosis of disease, facilitate patient selection for treatment, and monitor therapeutic response. In this activity, based on a recent live event, a panel of expert faculty provide training in the appropriate integration of validated and emerging cerebrospinal fluid (CSF) and plasma biomarkers into the AD diagnostic workup to identify early-stage AD in symptomatic patients. The faculty utilize a case-based approach to model the application and interpretation of fluid biomarkers in clinical practice, as well as highlight advantages and limitations associated with currently available and emerging CSF and plasma biomarkers. Upon completion of this activity, participants should be better able to: Apply validated fluid biomarkers to facilitate a timely neuropathological diagnosis of AD in symptomatic patients; Describe the limitations and advantages associated with currently available and emerging fluid diagnostics; and Integrate emerging plasma biomarkers into the diagnostic workup through appropriate application and accurate interpretation to improve early diagnosis and precision management of AD

Go online to PeerView.com/GAZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses strategies for optimizing the biomarker-based diagnosis of Alzheimer's disease early in the disease course and the selection of appropriate patients who might benefit from novel disease-modifying therapies, as well as a comprehensive care model for the multidisciplinary management of patients with Alzheimer's disease. Upon completion of this activity, participants should be better able to: Apply current and emerging diagnostic tools to optimize the biomarker-based diagnosis of AD early in the disease course; Select appropriate patients with AD who may benefit from novel disease-modifying therapies based on an understanding of their mechanisms of action, efficacy, and safety profiles; and Utilize a comprehensive care model to optimize the multidisciplinary management of patients with AD

Go online to PeerView.com/GAZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses strategies for optimizing the biomarker-based diagnosis of Alzheimer's disease early in the disease course and the selection of appropriate patients who might benefit from novel disease-modifying therapies, as well as a comprehensive care model for the multidisciplinary management of patients with Alzheimer's disease. Upon completion of this activity, participants should be better able to: Apply current and emerging diagnostic tools to optimize the biomarker-based diagnosis of AD early in the disease course; Select appropriate patients with AD who may benefit from novel disease-modifying therapies based on an understanding of their mechanisms of action, efficacy, and safety profiles; and Utilize a comprehensive care model to optimize the multidisciplinary management of patients with AD

Go online to PeerView.com/GAZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses strategies for optimizing the biomarker-based diagnosis of Alzheimer's disease early in the disease course and the selection of appropriate patients who might benefit from novel disease-modifying therapies, as well as a comprehensive care model for the multidisciplinary management of patients with Alzheimer's disease. Upon completion of this activity, participants should be better able to: Apply current and emerging diagnostic tools to optimize the biomarker-based diagnosis of AD early in the disease course; Select appropriate patients with AD who may benefit from novel disease-modifying therapies based on an understanding of their mechanisms of action, efficacy, and safety profiles; and Utilize a comprehensive care model to optimize the multidisciplinary management of patients with AD

Go online to PeerView.com/DEC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer's disease (AD) is a devastating yet highly prevalent condition, affecting 10% of people aged 65 years and older and increasing in prevalence as the population ages. Recent advances in disease-modifying therapies have allowed for the possibility of reductions in disease progression and improved patient outcomes. Significant advances have also been made in identifying and testing biomarkers for AD that may aid in the early diagnosis of disease, facilitate patient selection for treatment, and monitor therapeutic response. In this activity, based on a recent live event, a panel of expert faculty provide training in the appropriate integration of validated and emerging cerebrospinal fluid (CSF) and plasma biomarkers into the AD diagnostic workup to identify early-stage AD in symptomatic patients. The faculty utilize a case-based approach to model the application and interpretation of fluid biomarkers in clinical practice, as well as highlight advantages and limitations associated with currently available and emerging CSF and plasma biomarkers. Upon completion of this activity, participants should be better able to: Apply validated fluid biomarkers to facilitate a timely neuropathological diagnosis of AD in symptomatic patients; Describe the limitations and advantages associated with currently available and emerging fluid diagnostics; and Integrate emerging plasma biomarkers into the diagnostic workup through appropriate application and accurate interpretation to improve early diagnosis and precision management of AD

Eisai Co., Ltd. and Biogen Inc. announced on January 6th that under the Accelerated Approval Pathway the U.S. Food and Drug Administration (FDA) has approved lecanemab-irmb, which has the brand name in the United States of LEQEMBITM, for the treatment of Alzheimer's disease.  The approval is based on Phase 2 data that demonstrated that LEQEMBI reduced the accumulation of Aβ plaque in the brain, a defining feature of Alzheimer's disease.  Newt's guest is Dr. Marwan Sabbagh, MD.  He is a behavioral neurologist in the Alzheimer's and Memory Disorders Program and a professor in the Department of Neurology at Barrow Neurological Institute and was one of the leading doctors of the study.See omnystudio.com/listener for privacy information.

In this podcast episode, Marwan Sabbagh, MD, FAAN, and Marta San Luciano, MD, MS, FAAN, have a conversation about Parkinson's disease psychosis (PDP). Their discussion provides information on the disease itself—covering symptoms, risk factors, and mechanism—before moving into clinical strategies for diagnosis and disease and comorbidity management. The experts emphasize the importance of ruling out an underlying cause of psychosis before making a diagnosis of PDP, calling out common culprits such as urinary and respiratory tract infections. Following diagnosis, they comment on the value of implementing nonpharmacologic measures in tandem with pharmacologic interventions for PDP. Within the discussion of pharmacologic interventions, Drs Sabbagh and San Luciano give a well-rounded explanation of patient and medication factors they consider when choosing a treatment for their patients with PDP, including patient outcomes they have experienced in clinical practice. Rounding out the podcast, the experts touch on their approach to managing the very common comorbidity of sleep disturbances in patients with PDP.Presenters:Marwan Sabbagh, MD, FAANProfessor of NeurologyAlzheimer's and Memory Disorders DivisionDepartment of NeurologyBarrow Neurological InstitutePhoenix, ArizonaMarta San Luciano, MD, MS, FAANAssociate Professor of NeurologyUniversity of California, San FranciscoAttending NeurologistNeurology/Movement Disorders and Neuromodulation CenterUniversity of California, San Francisco Medical CenterSan Francisco, CaliforniaThis content is based on a CE/CME program supported by an independent educational grant from Acadia Pharmaceuticals, Inc.For additional activities in this program, visithttp://bit.ly/3tPMqnr

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Marwan Sabbagh, MD, FAAN, a behavioral neurologist at the Barrow Neurological Institute. He joined the show to discuss the clinical trial results for lecanemab that were presented at the Clinical Trials on Alzheimer's Disease meeting in San Francisco, the drug's overall efficacy profile, as well safety information and the rates of ARIA, and more. Lecanemab (Biogen/Eisai), is a humanized monoclonal antibody that eliminates toxic amyloid-ß protofibrils that is set to follow aducanumab as the next approved treatment for patients with early Alzheimer disease. The FDA is set to decide on the treatment's approval by January 6, 2023. In the phase 3 Clarity AD study (NCT01767311), one of the supporting trials for its new drug application, lecanemab showed a statistically significant 27% reduction in the primary end point of Clinical Dementia Rating-Sum of Boxes when compared with placebo over an 18-month treatment period (P = .00005). Investigators reported an ARIA-edema rate of 12.5% for those on lecanemab compared with 1.7% for those on placebo. Symptomatic ARIA-E occurred at a rate of 2.8% in the lecanemab group and 0.0% in the placebo group. Looking for more Alzheimer disease discussion? Check out the NeurologyLive® dementia/Alzheimer clinical focus page: neurologylive.com/clinical/dementia-alzheimer Episode Breakdown: 1:20 – Lecanemab's safety profile from Clarity AD 4:15 – Amyloid-related imaging abnormalities and lecanemab use 6:40 – The landscape of Alzheimer disease therapeutics 8:10 – Neurology News Minute 10:15 – What research has revealed about treatment approaches 13:00 – How clinical trials have evolved in dementia research 14:40 – The possibility of induction therapy in Alzheimer disease 16:30 – Looking ahead to the next steps in treatment development 18:00 – Progress toward treating Alzheimer disease earlier This episode is brought to you by the Giants of Multiple Sclerosis®. This premier neuroscience award program celebrates pioneers, innovators, and future generations of leaders for their remarkable achievements in Multiple Sclerosis. Nominations close January 31, 2023! Nominate: neurologylive.com/Giants-of-MS The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Roche Gets FDA Clearance for CSF Beta-Amyloid and Phospho-Tau Alzheimer Disease Assays BrainStorm Submits Type A Meeting Request Regarding NurOwn ALS Treatment Seizure-Free Days and Duration Intervals Increased with Fenfluramine in Dravet Syndrome Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. REFERENCE 1. Irizarry M, van Dyck C, Sabbagh M, Bateman R, Cohen S. Clarity AD: A phase 3 placebo-controlled, double-blind, parallel-group, 18-month study evaluating lecanemab in early Alzheimer disease. Presented at: CTAD Conference, November 29-Dec 2.

GET TRANSCRIPT AND FULL SHOWNOTES: antiaginghacks.net FullyVital Hair Wellness - Are you interested in getting thicker, fuller and longer hair using natural ingredients? Make sure to check out https://fullyvital.com to get the natural products that stimulate hair follicles in 4 unique ways. Use code ANTIAGINGHACKS to get 15% off your first order. Marwan Sabbagh, M.D. a board-certified neurologist and geriatric neurologist, is one of the nation's leading experts in Alzheimer's and dementia, and has been interviewed by AARP, NPR, Bloomberg, The Wall Street Journal, Prevention and other national media. Dr. Sabbagh is the author of The Alzheimer's Answer, The Alzheimer's Prevention Handbook, and coauthor of Fighting for My Life. His current book is titled Strong Heart, Sharp Mind published in 2022. Topics we discuss on this podcast: 3:10 Dr. Sabbagh's Background What's The Progression Of Alzheimers Disease? 6:10 Biomarker & Genetic Risk of Alzhiemers Disease 7:45 ApoE and it's risk for alzheimers disease 13:20 Why It's Important To Lower Hypertension 17:23 Are statins useful in Alzheimers disease 19:20 Prevention Lifestyle Factor #1: Physical Exercise 22:55 How Alzheimers Progresses In The Brain 25:35 What Are The Best Tests For Detecting Amyloid In The Brain 30:00 Prevention Lifestyle Factor #2: Mediterranean Diet 32:35 Prevention Lifestyle Factor #3: Good Sleep 34:40 Prevention Lifestyle Factor #4: Reduce Stress 36:20 Prevention Lifestyle Factor #5: Cognitive Stimulation 38:50 Prevention Lifestyle Factor #6: Social Connections 42:50 What's The Future Of Alzheimers? 45:40 Where To Find Dr. Sabbagh?

6 Effective Ways of Heart Disease Prevention Anyone who wishes to optimize health by protecting the heart and brain must listen to this! Dr. Marwan Sabbagh and Joe Piscatella combine the six most effective principles for heart disease prevention. They unfold valuable heart and brain facts in their new book Strong Heart, Sharp Mind, which are equally beneficial for the prevention of Alzheimer's disease. In a way, they open hope for effective heart disease treatments, dealing with Alzheimer's, and other brain ailments with a multidisciplinary approach. What is good for your heart is good for your brain and ultimately contributes to your overall healthy lifestyle. This episode guides listeners to optimal well-being using a 6-Step Brain-Body Balance Program. In this discussion, he adds that the mechanism that underpins heart disease symptoms considerably overlaps with the symptoms of Alzheimer's. Therefore, aggressively managing the cures for one has two or more benefits. How Is Heart Disease The # 1 Cause Of Death Worldwide? Researchers agreed that cardiovascular arrest, high blood pressure, and cholesterol are risk factors for many other diseases like Alzheimer's. High blood pressure is one of the mechanisms overlapping Alzheimer's and heart disease symptoms, making it the most deadly disease of all time. Dr. Sabbagh believes aggressively managing cholesterol and high blood pressure might considerably help heart disease prevention through natural anti-inflammatory processes. He adds that saturated fats are bad for the brain, which triggers amyloid (an unhealthy protein in the brain), hindering ongoing heart disease treatment. Is High Blood Pressure A Contributor to Heart Disease? National Academy of Sciences, Engineering, and Medicines analyzed the whole shebang, including diet, cognitive stimulation, exercise, health conditions, etc. They came up with their thorough and expert analysis that blood pressure management, mental stimulation, and exercise were the only three things that showed sufficient evidence to recommend them in clinical practices. Several other health organizations are researching, concluding that high blood pressure management is the ultimate risk reduction strategy for the heart and brain. What Are Neurobics? Neurobics are brain exercises that aid in healthy mental activities and prevent severe diseases such as Alzheimer's and heart disease. Dr. Sabbagh suggests Neurobics as a way of simultaneously doing physical activity and cognitive stimulation. In the book, the author outlines the perfect Neurobics that can improve heart function and blood vessel health. Transforming The American Diet into A Healthful Way to Eat According to Berkeley Wellness Letter, Nutrition Actions, and Tufts Newsletter, modest dietary changes can help fight heart disease symptoms. Similarly, one fish meal a week, two berries a week, and two vegetables a day can reduce Alzheimer's disease risk. Managing Alzheimer's with A Good Sleep Regimen Sleep apnea is a huge risk for heart attacks as well as a considerable risk for cognitive decline. Quality sleep is the procedure by which your brain removes the amyloids. That's why Dr. Sabbagh refers to sleep as an easy fix to our mild cognitive illness. Exercise during the daytime, regular meal times, waking up, and going to bed are far more beneficial than sleeping pills. Also, there is a link between inadequate sleep quality, plaque building, and high blood pressure. How Stress Management Is Vital To Defeat Heart Diseases A person's mental health can positively or negatively impact their physical health, and the risk of heart failure may increase with high blood pressure. So, they refer to a phenomenon called 'hippie genetics,' which has secondary benefits in dealing with stress and reducing risks for heart disease. As said, you are more likely to be stress-free if you are physically active and socially connected, leading a healthy lifestyle. Keep your heart pumping and passions alive by knowing what is good for you. If you have people that support you and share the same bond, you are more likely to be mentally healthy. The people who practice cognitive stimulation are the people who exercise and eat right and ultimately lead a healthy lifestyle. However, it is more important to practice mental stimulation even if you have heart disease symptoms or Alzheimer's. The book gives you a great plan to follow that. About the Guest: Marwan Noel Sabbagh, M.D, formerly the Director of the Lou Ruvo Center for Brain Health at Cleveland Clinic, is internationally known for his expertise in the brain and vascular disorders like Alzheimer's and related dementias. For more information about your assessment options for cognitive issues or Alzheimer's, contact Kemper Cognitive Wellness in Cleveland, Ohio. Email: info@kemperwellness.com Website: https://kemperwellness.com/ Phone: (216) 337-1400.

This episode is brought to you by Athletic Greens and ButcherBox. For so long, we've been told that memory loss and dementia are just normal parts of aging.We now know it doesn't have to be that way, and that there are many measures we can proactively take to avoid cognitive decline as we age. Emerging research is helping us look at new ways to treat and even prevent devastating neurological diseases like Alzheimer's and dementia, giving people a newfound sense of hope. In today's episode, I talk with Dr. Marwan Sabbagh, Dr. Richard Isaacson, and Dr. Jay Lombard about the role of genetics in brain disorders, lifestyle habits you can start right now to reduce your risk or reverse symptoms, and why we need to look at bacteria as a cause of neurodegenerative disease. Dr. Marwan Sabbagh is a board-certified neurologist and considered one of the leading experts in Alzheimer's and dementia. He is on the editorial board for the Journal of Alzheimer's Disease and BMC Neurology and is now Editor-in-Chief of Neurology and Therapy. Dr. Sabbagh is the author of The Alzheimer's Answer: Reduce Your Risk and Keep Your Brain Healthy and The Alzheimer's Prevention Cookbook: 100 Recipes to Boost Brain Health. His latest book, Fighting for My Life: How to Thrive in the Shadow of Alzheimer's, is now available.Dr. Richard Isaacson serves as Director of the Center for Brain Health and Director of the Alzheimer's Prevention Clinic (APC) at Florida Atlantic University's Schmidt College of Medicine. He previously served as Director of the APC at the Weill Cornell Memory Disorders Program, Assistant Dean of Faculty Development, and Associate Professor of Neurology at Weill Cornell Medicine and New York-Presbyterian. He remains as Adjunct Associate Professor of Neurology in the Department of Neurology at Weill Cornell. Dr. Jay Lombard is an internationally acclaimed neurologist, author, and keynote speaker specializing in neuroimmunological conditions and medical mysteries. Dr. Lombard integrates biological, psychological, and existential components in his holistic treatment approach. Dr. Lombard's clinical experience revealed an interesting pattern: one patient with ALS also had small-intestine bacterial overgrowth, another had ulcerative colitis, yet another had Crohn's, and so on. He started seeing the connections between these bacterial imbalances and Clostridium difficile, or C. diff, and the link to neurological symptoms. This episode is brought to you by Athletic Greens and ButcherBox.Right now, when you purchase AG1 from Athletic Greens, you will receive 10 FREE travel packs with your first purchase by visiting athleticgreens.com/hyman.When you sign up today, ButcherBox will send you two pounds of sustainably caught, wild Alaskan salmon in your first box for free. To receive this offer, go to ButcherBox.com/farmacy.Full-length episodes of these interviews can be found here:Dr. Marwan SabbaghDr. Richard IsaacsonDr. Jay Lombard See acast.com/privacy for privacy and opt-out information.

The gravest health threats to the nearly 109 million Americans over 50 are heart disease (the nation's leading killer), and Alzheimer's (the most feared affliction that affects millions of families.) In his new book Strong Heart, Sharp Mind, noted neurologist Dr. Marwan Sabbagh, reveals new hope for treating and preventing these dreaded conditions together.Strong Heart, Sharp Mind relies on the latest science to reveal a proven 6-step program to maximize and improve both heart and brain health. The program includes:· Incorporating exercise into daily activities· Transforming the American diet into a healthful way to eat· Building a healthy sleep regimen· Managing stress, anger, and anxiety· Creating opportunities for cognitive stimulation· Bolstering your social support system

The gravest health threats to the nearly 109 million Americans over 50 are heart disease and Alzheimer's.The gravest health threats to the nearly 109 million Americans over 50 are heart disease (the nation's leading killer), and Alzheimer's (the most feared affliction that affects millions of families.) In his new book Strong Heart, Sharp Mind, noted neurologist Dr. Marwan Sabbagh, reveals new hope for treating and preventing these dreaded conditions together.Strong Heart, Sharp Mind relies on the latest science to reveal a proven 6-step program to maximize and improve both heart and brain health. The program includes:· Incorporating exercise into daily activities· Transforming the American diet into a healthful way to eat· Building a healthy sleep regimen· Managing stress, anger, and anxiety· Creating opportunities for cognitive stimulation· Bolstering your social support system

6 step programme that reverses heart disease & helps prevent Alzheimer's

The gravest health threats to the nearly 109 million Americans over 50 are heart disease and Alzheimer's.The gravest health threats to the nearly 109 million Americans over 50 are heart disease (the nation's leading killer), and Alzheimer's (the most feared affliction that affects millions of families.) In his new book Strong Heart, Sharp Mind, noted neurologist Dr. Marwan Sabbagh, reveals new hope for treating and preventing these dreaded conditions together.Strong Heart, Sharp Mind relies on the latest science to reveal a proven 6-step program to maximize and improve both heart and brain health. The program includes:· Incorporating exercise into daily activities· Transforming the American diet into a healthful way to eat· Building a healthy sleep regimen· Managing stress, anger, and anxiety· Creating opportunities for cognitive stimulation· Bolstering your social support system

Dr. Marwan Sabbagh is a board-certified Geriatric Neurologist at the Cleveland Clinic Lou Ruvo Center for Brain Health, specializing in Alzheimer's disease and other forms of dementia. He has dedicated himself to finding a cure for Alzheimer's and similar neurodegenerative diseases. His expertise has earned him the position as the Camille and Larry Ruvo Endowed Chair for Brain Health.  Dr. Sabbagh authored the book, The Alzheimer's Answer: Reduce Your Risk and Keep Your Brain Healthy, which translates his research into practical advice to help cognitive function for his readers. In addition, he has written and co-written over 300 scientific articles on research surrounding Alzheimer's. In this episode… There are many diseases that were once written off as incurable, but can now be managed through innovations in science and medicine. Take diabetes as an example, which once had a high mortality rate. Now, most people with diabetes are able to live normal lives. However, when it comes to Alzheimer's, the best-case scenario is slowing down the process for someone — or is it?  Recently, there has been research that suggests a better solution is on the way. Whether it's through early tests or advanced treatment, these neurodegenerative diseases might soon be manageable. Want to know more? Dr. Mark Syms hosts Dr. Marwan Sabbagh, a board-certified Geriatric Neurologist at the Cleveland Clinic Lou Ruvo Center for Brain Health, to learn about the new research on Alzheimer's and other neurodegenerative diseases. They talk about the recent developments with blood tests and medicine from leaders in the field. They also go over ways to reduce your risk of diagnosis and advice for family members with early symptoms. Find out more on this episode of the ListenUp! podcast.

In this episode, we hear the argument in favor of the new Alzheimer's drug, Aducanumab (Aduhelm).  Dr. Marwan Sabbagh is a clinical and research leader at the Cleveland Clinic's Lou Ruvo Center for Brain Health. He was a doctor that saw patients in one of the trials that led to the FDA's Accelerated (provisional) Approval.  Note: Dr. Sabbagh notes his disclosure as an advisor to Biogen, the maker of Aducanumab. We discuss what Dr. Sabbagh noted in his own patients involved in the recent Phase 3 clinical trial of Aducanumab. Controversy over the FDA's decision and why Dr. Sabbagh's 25+ years of diagnosing and treating Alzheimer's makes him optimistic about this drug. Dr. Sabbagh talks through who he thinks might be a good candidate for Aducanumab, the drug's known practical side effects, and how people might get access to the medication in the near future. Ultimately, Dr. Sabbagh sees people in the near future living with Alzheimer's like a chronic disease much like HIV or diabetes, or even cancer. This episode presents a slightly different perspective than many of our listeners are used to.  We hope you find it useful.   2:33 - what is this new drug and how does it actually treat Alzheimer's  5:28 - Why Dr. Sabbagh is optimistic about this new drug  11:43 - Reasons for some of the skepticism around the study  14:11 - Dr. Sabbagh's observations of the people who have taken the drug  21:10 - What are the risks of taking the drug?  27:08 - Responding to the criticism of the drug  32:30 - Other promising drugs that may be available in the future for Alzheimer's patients  37:18 - How do people get access to this new drug? 

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this episode, we spoke with a number of people in the Alzheimer disease field with varying and nuanced opinions on this decision to better understand not only what this approval means for the clinical care of patients, but what the downstream effects of it may be. Those individuals, in order of appearance, are:  Marwan Sabbagh, MD, director, Cleveland Clinic Lou Ruvo Center for Brain Health, and investigator in the aducanumab trials Anton P. Porsteinsson, MD, director, Alzheimer's Disease Care, Research and Education Program, University of Rochester School of Medicine and Dentistry, and investigator in the aducanumab trials David Knopman, MD, professor of neurology, Mayo Clinic, and investigator in the aducanumab trials Lon Schneider, MD, MS, professor of Psychiatry and the Behavioral Sciences, and Della Martin Chair in Psychiatry and Neuroscience, University of Southern California Keck School of Medicine Robert Howard, MD, MRCPsych, Professor of Old Age Psychiatry, Faculty of Brain Sciences, University College London Ian Kremer, JD, executive director, LEAD Coalition Douglas Scharre, MD, neurologist and director, Division of Cognitive Neurology, Ohio State Wexner Medical Center Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. For more insight and NeurologyLive coverage of aducanumab, click here. 

Go online to PeerView.com/FMQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer's disease (AD) is a devastating yet highly prevalent condition, affecting 10% of people older than 65 years and increasing in global prevalence as the world's population ages. Given the heavy economic and societal burdens of AD, major emphasis has been placed on finding disease-modifying therapies that can successfully delay or prevent the progression of AD. Although several hypotheses have been proposed regarding the causes of AD, the amyloid cascade hypothesis and the tau propagation hypothesis have gained the most support, and there are many novel agents under investigation for the treatment of AD that target Aβ or tau in a variety of ways. Recent advances have also been made in identifying and testing biomarkers for AD that may aid in the early diagnosis of disease, facilitate patient selection for treatment, and monitor therapeutic response. This accredited PeerView on-demand activity is based on a virtual meeting that utilized the innovative Pando™ platform. A multidisciplinary panel of AD experts provides an engaging discussion on the early recognition and diagnosis of AD, current and emerging treatment options and biomarkers, and optimal multidisciplinary management of patients with AD. They also explore ways in which different members of the multidisciplinary team can help to accommodate the influx of new treatable patients that will flood the healthcare system once a disease-modifying therapy is approved for AD. Upon completion of this activity, participants will be able to: Describe the rationale for screening for mild cognitive impairment (MCI) to identify patients at risk for AD early in the disease course, Apply validated neuroimaging techniques and biomarkers to make etiologically based diagnoses of AD, Assess key data sets on the efficacy, safety, and tolerability of available and emerging therapies for the treatment of AD, Employ a multidisciplinary team-based approach to manage the influx of patients that will need to be screened, diagnosed, and treated once a disease-modifying therapy is approved in AD.

Go online to PeerView.com/FMQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer's disease (AD) is a devastating yet highly prevalent condition, affecting 10% of people older than 65 years and increasing in global prevalence as the world's population ages. Given the heavy economic and societal burdens of AD, major emphasis has been placed on finding disease-modifying therapies that can successfully delay or prevent the progression of AD. Although several hypotheses have been proposed regarding the causes of AD, the amyloid cascade hypothesis and the tau propagation hypothesis have gained the most support, and there are many novel agents under investigation for the treatment of AD that target Aβ or tau in a variety of ways. Recent advances have also been made in identifying and testing biomarkers for AD that may aid in the early diagnosis of disease, facilitate patient selection for treatment, and monitor therapeutic response. This accredited PeerView on-demand activity is based on a virtual meeting that utilized the innovative Pando™ platform. A multidisciplinary panel of AD experts provides an engaging discussion on the early recognition and diagnosis of AD, current and emerging treatment options and biomarkers, and optimal multidisciplinary management of patients with AD. They also explore ways in which different members of the multidisciplinary team can help to accommodate the influx of new treatable patients that will flood the healthcare system once a disease-modifying therapy is approved for AD. Upon completion of this activity, participants will be able to: Describe the rationale for screening for mild cognitive impairment (MCI) to identify patients at risk for AD early in the disease course, Apply validated neuroimaging techniques and biomarkers to make etiologically based diagnoses of AD, Assess key data sets on the efficacy, safety, and tolerability of available and emerging therapies for the treatment of AD, Employ a multidisciplinary team-based approach to manage the influx of patients that will need to be screened, diagnosed, and treated once a disease-modifying therapy is approved in AD.

Go online to PeerView.com/FMQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer's disease (AD) is a devastating yet highly prevalent condition, affecting 10% of people older than 65 years and increasing in global prevalence as the world's population ages. Given the heavy economic and societal burdens of AD, major emphasis has been placed on finding disease-modifying therapies that can successfully delay or prevent the progression of AD. Although several hypotheses have been proposed regarding the causes of AD, the amyloid cascade hypothesis and the tau propagation hypothesis have gained the most support, and there are many novel agents under investigation for the treatment of AD that target Aβ or tau in a variety of ways. Recent advances have also been made in identifying and testing biomarkers for AD that may aid in the early diagnosis of disease, facilitate patient selection for treatment, and monitor therapeutic response. This accredited PeerView on-demand activity is based on a virtual meeting that utilized the innovative Pando™ platform. A multidisciplinary panel of AD experts provides an engaging discussion on the early recognition and diagnosis of AD, current and emerging treatment options and biomarkers, and optimal multidisciplinary management of patients with AD. They also explore ways in which different members of the multidisciplinary team can help to accommodate the influx of new treatable patients that will flood the healthcare system once a disease-modifying therapy is approved for AD. Upon completion of this activity, participants will be able to: Describe the rationale for screening for mild cognitive impairment (MCI) to identify patients at risk for AD early in the disease course, Apply validated neuroimaging techniques and biomarkers to make etiologically based diagnoses of AD, Assess key data sets on the efficacy, safety, and tolerability of available and emerging therapies for the treatment of AD, Employ a multidisciplinary team-based approach to manage the influx of patients that will need to be screened, diagnosed, and treated once a disease-modifying therapy is approved in AD.

Go online to PeerView.com/FMQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer's disease (AD) is a devastating yet highly prevalent condition, affecting 10% of people older than 65 years and increasing in global prevalence as the world's population ages. Given the heavy economic and societal burdens of AD, major emphasis has been placed on finding disease-modifying therapies that can successfully delay or prevent the progression of AD. Although several hypotheses have been proposed regarding the causes of AD, the amyloid cascade hypothesis and the tau propagation hypothesis have gained the most support, and there are many novel agents under investigation for the treatment of AD that target Aβ or tau in a variety of ways. Recent advances have also been made in identifying and testing biomarkers for AD that may aid in the early diagnosis of disease, facilitate patient selection for treatment, and monitor therapeutic response. This accredited PeerView on-demand activity is based on a virtual meeting that utilized the innovative Pando™ platform. A multidisciplinary panel of AD experts provides an engaging discussion on the early recognition and diagnosis of AD, current and emerging treatment options and biomarkers, and optimal multidisciplinary management of patients with AD. They also explore ways in which different members of the multidisciplinary team can help to accommodate the influx of new treatable patients that will flood the healthcare system once a disease-modifying therapy is approved for AD. Upon completion of this activity, participants will be able to: Describe the rationale for screening for mild cognitive impairment (MCI) to identify patients at risk for AD early in the disease course, Apply validated neuroimaging techniques and biomarkers to make etiologically based diagnoses of AD, Assess key data sets on the efficacy, safety, and tolerability of available and emerging therapies for the treatment of AD, Employ a multidisciplinary team-based approach to manage the influx of patients that will need to be screened, diagnosed, and treated once a disease-modifying therapy is approved in AD.

Go online to PeerView.com/FMQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer's disease (AD) is a devastating yet highly prevalent condition, affecting 10% of people older than 65 years and increasing in global prevalence as the world's population ages. Given the heavy economic and societal burdens of AD, major emphasis has been placed on finding disease-modifying therapies that can successfully delay or prevent the progression of AD. Although several hypotheses have been proposed regarding the causes of AD, the amyloid cascade hypothesis and the tau propagation hypothesis have gained the most support, and there are many novel agents under investigation for the treatment of AD that target Aβ or tau in a variety of ways. Recent advances have also been made in identifying and testing biomarkers for AD that may aid in the early diagnosis of disease, facilitate patient selection for treatment, and monitor therapeutic response. This accredited PeerView on-demand activity is based on a virtual meeting that utilized the innovative Pando™ platform. A multidisciplinary panel of AD experts provides an engaging discussion on the early recognition and diagnosis of AD, current and emerging treatment options and biomarkers, and optimal multidisciplinary management of patients with AD. They also explore ways in which different members of the multidisciplinary team can help to accommodate the influx of new treatable patients that will flood the healthcare system once a disease-modifying therapy is approved for AD. Upon completion of this activity, participants will be able to: Describe the rationale for screening for mild cognitive impairment (MCI) to identify patients at risk for AD early in the disease course, Apply validated neuroimaging techniques and biomarkers to make etiologically based diagnoses of AD, Assess key data sets on the efficacy, safety, and tolerability of available and emerging therapies for the treatment of AD, Employ a multidisciplinary team-based approach to manage the influx of patients that will need to be screened, diagnosed, and treated once a disease-modifying therapy is approved in AD.

Go online to PeerView.com/FMQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer's disease (AD) is a devastating yet highly prevalent condition, affecting 10% of people older than 65 years and increasing in global prevalence as the world's population ages. Given the heavy economic and societal burdens of AD, major emphasis has been placed on finding disease-modifying therapies that can successfully delay or prevent the progression of AD. Although several hypotheses have been proposed regarding the causes of AD, the amyloid cascade hypothesis and the tau propagation hypothesis have gained the most support, and there are many novel agents under investigation for the treatment of AD that target Aβ or tau in a variety of ways. Recent advances have also been made in identifying and testing biomarkers for AD that may aid in the early diagnosis of disease, facilitate patient selection for treatment, and monitor therapeutic response. This accredited PeerView on-demand activity is based on a virtual meeting that utilized the innovative Pando™ platform. A multidisciplinary panel of AD experts provides an engaging discussion on the early recognition and diagnosis of AD, current and emerging treatment options and biomarkers, and optimal multidisciplinary management of patients with AD. They also explore ways in which different members of the multidisciplinary team can help to accommodate the influx of new treatable patients that will flood the healthcare system once a disease-modifying therapy is approved for AD. Upon completion of this activity, participants will be able to: Describe the rationale for screening for mild cognitive impairment (MCI) to identify patients at risk for AD early in the disease course, Apply validated neuroimaging techniques and biomarkers to make etiologically based diagnoses of AD, Assess key data sets on the efficacy, safety, and tolerability of available and emerging therapies for the treatment of AD, Employ a multidisciplinary team-based approach to manage the influx of patients that will need to be screened, diagnosed, and treated once a disease-modifying therapy is approved in AD.

Dementia is a broad term which covers many conditions, including Alzheimer's disease, vascular dementia, frontotemporal dementia, and others. In this episode, Marwan Sabbagh, MD provides insights around diagnostic criteria for the most common dementias, as well as their differential features.

CME credits: 0.25 Valid until: 15-01-2022 Claim your CME credit at https://reachmd.com/programs/cme/new-horizons-alzheimers-disease/12108/ Once an Alzheimer's disease diagnosis is made, the next challenge is treatment. Dr. Alizera Atri and Dr. Marwan Sabbagh discuss the current standard of care, the clinical pipeline for Alzheimer's disease, and the role of amyloid-beta-targeted antibodies.

Go online to PeerView.com/QCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dementia-related psychosis discusses current guidelines and emerging therapeutic strategies for the treatment of dementia-related psychosis. Upon completion of this activity, participants should be better able to: Employ established tools and current criteria to accurately recognize and diagnose psychosis in patients with dementia, Assess key data sets on the efficacy, safety, and tolerability of available and emerging treatment approaches for the management of dementia-related psychosis (DRP), Select individualized nonpharmacological and/or pharmacological treatments for DRP based on patients' specific needs and circumstances.

Go online to PeerView.com/QCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dementia-related psychosis discusses current guidelines and emerging therapeutic strategies for the treatment of dementia-related psychosis. Upon completion of this activity, participants should be better able to: Employ established tools and current criteria to accurately recognize and diagnose psychosis in patients with dementia, Assess key data sets on the efficacy, safety, and tolerability of available and emerging treatment approaches for the management of dementia-related psychosis (DRP), Select individualized nonpharmacological and/or pharmacological treatments for DRP based on patients' specific needs and circumstances.

Go online to PeerView.com/QCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dementia-related psychosis discusses current guidelines and emerging therapeutic strategies for the treatment of dementia-related psychosis. Upon completion of this activity, participants should be better able to: Employ established tools and current criteria to accurately recognize and diagnose psychosis in patients with dementia, Assess key data sets on the efficacy, safety, and tolerability of available and emerging treatment approaches for the management of dementia-related psychosis (DRP), Select individualized nonpharmacological and/or pharmacological treatments for DRP based on patients' specific needs and circumstances.

Go online to PeerView.com/QCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dementia-related psychosis discusses current guidelines and emerging therapeutic strategies for the treatment of dementia-related psychosis. Upon completion of this activity, participants should be better able to: Employ established tools and current criteria to accurately recognize and diagnose psychosis in patients with dementia, Assess key data sets on the efficacy, safety, and tolerability of available and emerging treatment approaches for the management of dementia-related psychosis (DRP), Select individualized nonpharmacological and/or pharmacological treatments for DRP based on patients' specific needs and circumstances.

Transcript: DementiaSherpa.com/Episode104. Jamie Tyrone was first on the show in episode 100: Enjoy Us in the Moment, where she used her own experiences to offer some creative, real-life examples of how to hit it out of the park as a care partner. Several years ago, Jamie was exhibiting symptoms of MS and given the diagnosis. But something still seemed amiss. She was determined to unravel the mystery, and that's where we pick up Jamie's remarkable and inspiring story in this episode.  A trained nurse and former marketing executive, Jamie's now a full time advocate for Alzheimer's research. She has two copies of the ApoE-4 gene, which puts her at a 91% lifetime risk of getting Alzheimer's disease, along with 2% of the US population.  Jamie is the co-author a new book with Dr Marwan Sabbagh, Fighting for My Life: How to Thrive in the Shadow of Alzheimer's.  She is also the CEO and founder of Beating Alzheimer's by Embracing Science (B.A.B.E.S.), a nonprofit organization that raises funds and awareness for Alzheimer's research.  In addition, Jamie is a founding member of Women Against Alzheimer's and has contributed recommendations to the National Alzheimer's Project Act Advisory Council.  

Taking Stock of Potential Advances in the Early Diagnosis of Alzheimer's Disease: What Are the Implications for Treatment?

Taking Stock of Potential Advances in the Early Diagnosis of Alzheimer's Disease: What Are the Implications for Treatment?

Taking Stock of Potential Advances in the Early Diagnosis of Alzheimer's Disease: What Are the Implications for Treatment?

Taking Stock of Potential Advances in the Early Diagnosis of Alzheimer's Disease: What Are the Implications for Treatment?

Taking Stock of Potential Advances in the Early Diagnosis of Alzheimer's Disease: What Are the Implications for Treatment?

Taking Stock of Potential Advances in the Early Diagnosis of Alzheimer's Disease: What Are the Implications for Treatment?

Taking Stock of Potential Advances in the Early Diagnosis of Alzheimer's Disease: What Are the Implications for Treatment?

Taking Stock of Potential Advances in the Early Diagnosis of Alzheimer's Disease: What Are the Implications for Treatment?

Host: Matt Birnholz, MD Guest: Marwan Noel Sabbagh, MD, FAAN, CCRI In efforts to detect and diagnose Alzheimer's Disease, time is of the essence. But there are numerous barriers that clinicians face in practice to establishing a diagnosis quickly and accurately, which affects quality of care for patients. Joining host Dr. Matt Birnholz to address and consider solutions for these barriers is Dr. Marwan Sabbagh, Professor of Neurology and Chief of the Memory Disorders Division at the Barrow Neurological Institute. Uncover the truth about Alzheimer's in the non-certified educational series, Alzheimer's Disease: Towards Earlier Detection

Host: Matt Birnholz, MD Guest: Marwan Noel Sabbagh, MD, FAAN, CCRI Dr. Marwan Sabbagh, Professor of Neurology and Chief of the Memory Disorders Division at Barrow Neurological Institute, describes some of his key priorities for the current and future state of Alzheimer's care. Uncover the truth about Alzheimer's in the non-certified educational series, Alzheimer's Disease: Towards Earlier Detection

Host: Matt Birnholz, MD Guest: Marwan Noel Sabbagh, MD, FAAN, CCRI In efforts to detect and diagnose Alzheimer's Disease, time is of the essence. But there are numerous barriers that clinicians face in practice to establishing a diagnosis quickly and accurately, which affects quality of care for patients. Joining host Dr. Matt Birnholz to address and consider solutions for these barriers is Dr. Marwan Sabbagh, Professor of Neurology and Chief of the Memory Disorders Division at the Barrow Neurological Institute. Uncover the truth about Alzheimer's in the non-certified educational series, Alzheimer's Disease: Towards Earlier Detection

Host: Matt Birnholz, MD Guest: Marwan Noel Sabbagh, MD, FAAN, CCRI Dr. Marwan Sabbagh, Professor of Neurology and Chief of the Memory Disorders Division at Barrow Neurological Institute, describes some of his key priorities for the current and future state of Alzheimer's care. Uncover the truth about Alzheimer's in the non-certified educational series, Alzheimer's Disease: Towards Earlier Detection

Host: Matt Birnholz, MD Guest: Marwan Noel Sabbagh, MD, FAAN, CCRI In efforts to detect and diagnose Alzheimer's Disease, time is of the essence. But there are numerous barriers that clinicians face in practice to establishing a diagnosis quickly and accurately, which affects quality of care for patients. Joining host Dr. Matt Birnholz to address and consider solutions for these barriers is Dr. Marwan Sabbagh, Professor of Neurology and Chief of the Memory Disorders Division at the Barrow Neurological Institute. Uncover the truth about Alzheimer's in the non-certified educational series, Alzheimer's Disease: Towards Earlier Detection

Host: Matt Birnholz, MD Guest: Marwan Noel Sabbagh, MD, FAAN, CCRI Dr. Marwan Sabbagh, Professor of Neurology and Chief of the Memory Disorders Division at Barrow Neurological Institute, describes some of his key priorities for the current and future state of Alzheimer's care. Uncover the truth about Alzheimer's in the non-certified educational series, Alzheimer's Disease: Towards Earlier Detection